Inositol and Metformin Administration in Mediterranean Diet and Low-Carbohydrate Diets in Women With PCOS
Comparison of Inositol and Metformin Administration in Mediterranean Diet and Low-Carbohydrate Diets in Women With Polycystic Ovary Syndrome
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Szczegółowy opis
Typ studiów
Typ studiów
Zapisy (Szacowany)
Zapisy
Faza
Faza
- Nie dotyczy
Kontakty i lokalizacje
Kontakt w sprawie studiów
Kontakt w sprawie studiów
- Nazwa: Esra Ucar, MSc
- Numer telefonu: +90 555 993 1894
- E-mail: esra.ucar@dicle.edu.tr
Lokalizacje studiów
-
-
Diyarbakır
-
Diyarbakır, Diyarbakır, Turcja (Türkiye), 21280
- Dicle University Hospital
-
Kontakt:
- Elif Agacayak, MD
- Numer telefonu: +90 505 943 3449
- E-mail: drelifagacayak@gmail.com
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
- Dorosły
Akceptuje zdrowych ochotników
Opis
Inclusion Criteria:
- Women aged 20-40
- Diagnosed with PCOS (Rotterdam, 2004)
- Insulin resistant (newly diagnosed or diagnosed within the last 3 months)
- Obese according to the World Health Organization (2006) in grades 1 and 2 (BMI: 30-40 kg/m²)
Exclusion Criteria:
- Pregnant or breastfeeding women
- Those undergoing/contemplating IVF treatment
- Early menopause diagnosis
- Diabetes diagnosis, use of oral antidiabetic agents
- Chronic diseases (liver, kidney diseases, cancer)
- Psychiatric illnesses
- Those taking routine medication for any reason
- Use of hormonal contraceptive methods within the last 3 months
- Active smokers and alcohol users or social drinkers
- Change in body weight of more than 10% in the last 6 months for any reason
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Liczba ramion
Broń i interwencje
Grupa uczestników / ArmGrupa uczestników / Arm |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Eksperymentalny: Group Receiving Mediterranean Diet and Inositol Supplement
Participants in this arm will receive a hypocaloric Mediterranean diet combined with a myo-inositol supplement containing folic acid.
The supplement will be administered orally as two sachets daily, providing a total daily dose of 4000 mg myo-inositol and 400 µg folic acid.
The intervention period will be 2 months.
|
Myo-inositol will be administered orally as a powdered sachet formulation.
Participants will receive two sachets daily for 2 months, providing a total daily dose of 4000 mg myo-inositol and 400 µg folic acid.
Participants will receive individualized hypocaloric Mediterranean diet counseling for 2 months.
Daily energy requirements will be calculated individually, and meal plans will be prescribed with an energy deficit of approximately 500 kcal/day to promote weight loss.
The dietary pattern will emphasize vegetables, fruits, whole grains, legumes, nuts, olive oil as the principal source of fat, moderate consumption of fish, poultry, and low-fat dairy products, and limited consumption of red and processed meat, refined grains, and foods high in added sugars and saturated fat.
Dietary adherence will be monitored at regular follow-up visits throughout the intervention period.
|
|
Eksperymentalny: Group Receiving Mediterranean Diet and Metformin Treatment
Participants in this arm will receive a hypocaloric Mediterranean diet combined with metformin and folic acid supplementation.
Metformin will be administered orally at a dose of 500 mg once daily during the first week and increased to 1000 mg/day (500 mg twice daily) from the second week onward, as tolerated.
Folic acid will be administered orally at a dose of 400 µg once daily.
Folic acid is included to standardize folate intake across intervention groups, as the myo-inositol supplement used in the inositol groups also contains folic acid.
The intervention period will be 2 months.
|
Participants will receive individualized hypocaloric Mediterranean diet counseling for 2 months.
Daily energy requirements will be calculated individually, and meal plans will be prescribed with an energy deficit of approximately 500 kcal/day to promote weight loss.
The dietary pattern will emphasize vegetables, fruits, whole grains, legumes, nuts, olive oil as the principal source of fat, moderate consumption of fish, poultry, and low-fat dairy products, and limited consumption of red and processed meat, refined grains, and foods high in added sugars and saturated fat.
Dietary adherence will be monitored at regular follow-up visits throughout the intervention period.
Metformin will be administered orally for 2 months.
Treatment will begin at 500 mg once daily during the first week and will be increased to 1000 mg/day (500 mg twice daily) from the second week onward, as tolerated.
Dose escalation is intended to improve gastrointestinal tolerability while achieving the target maintenance dose.
Folic acid will be administered orally at a dose of 400 µg once daily for 2 months.
Folic acid is provided to participants in the metformin and control groups to standardize folate intake across intervention groups, as the myo-inositol supplement administered in the inositol groups also contains 400 µg of folic acid per day.
|
|
Aktywny komparator: Mediterranean Diet Active Control Group
Participants in this arm will receive a hypocaloric Mediterranean diet together with folic acid supplementation.
Folic acid will be administered orally at a dose of 400 µg once daily.
No metformin or myo-inositol supplementation will be provided.
Folic acid is included to standardize folate intake across intervention groups, as the myo-inositol supplement used in the inositol groups also contains folic acid.
The intervention period will be 2 months.
|
Participants will receive individualized hypocaloric Mediterranean diet counseling for 2 months.
Daily energy requirements will be calculated individually, and meal plans will be prescribed with an energy deficit of approximately 500 kcal/day to promote weight loss.
The dietary pattern will emphasize vegetables, fruits, whole grains, legumes, nuts, olive oil as the principal source of fat, moderate consumption of fish, poultry, and low-fat dairy products, and limited consumption of red and processed meat, refined grains, and foods high in added sugars and saturated fat.
Dietary adherence will be monitored at regular follow-up visits throughout the intervention period.
Folic acid will be administered orally at a dose of 400 µg once daily for 2 months.
Folic acid is provided to participants in the metformin and control groups to standardize folate intake across intervention groups, as the myo-inositol supplement administered in the inositol groups also contains 400 µg of folic acid per day.
|
|
Eksperymentalny: Group Receiving Low-Carbohydrate Diet and Inositol Supplement
Participants in this arm will receive a hypocaloric low-carbohydrate diet combined with a myo-inositol supplement containing folic acid.
The supplement will be administered orally as two sachets daily, providing a total daily dose of 4000 mg myo-inositol and 400 µg folic acid.
The intervention period will be 2 months.
|
Myo-inositol will be administered orally as a powdered sachet formulation.
Participants will receive two sachets daily for 2 months, providing a total daily dose of 4000 mg myo-inositol and 400 µg folic acid.
Participants will receive individualized hypocaloric low-carbohydrate diet counseling for 2 months.
Daily energy requirements will be calculated individually, and meal plans will be prescribed with an energy deficit of approximately 500 kcal/day to promote weight loss.
The diet will provide 50-130 g/day of carbohydrates or approximately 25-30% of total daily energy from carbohydrates.
After achieving the carbohydrate target, the remaining energy intake will be distributed to provide approximately 15-30% of total energy from protein and 35-50% from fat, according to individual energy requirements.
Dietary adherence will be monitored at regular follow-up visits throughout the intervention period.
|
|
Eksperymentalny: Group Receiving Low-Carbohydrate Diet and Metformin Treatment
Participants in this arm will receive a hypocaloric low-carbohydrate diet combined with metformin and folic acid supplementation.
Metformin will be administered orally at a dose of 500 mg once daily during the first week and increased to 1000 mg/day (500 mg twice daily) from the second week onward, as tolerated.
Folic acid will be administered orally at a dose of 400 µg once daily.
Folic acid is included to standardize folate intake across intervention groups, as the myo-inositol supplement used in the inositol groups also contains folic acid.
The intervention period will be 2 months.
|
Metformin will be administered orally for 2 months.
Treatment will begin at 500 mg once daily during the first week and will be increased to 1000 mg/day (500 mg twice daily) from the second week onward, as tolerated.
Dose escalation is intended to improve gastrointestinal tolerability while achieving the target maintenance dose.
Folic acid will be administered orally at a dose of 400 µg once daily for 2 months.
Folic acid is provided to participants in the metformin and control groups to standardize folate intake across intervention groups, as the myo-inositol supplement administered in the inositol groups also contains 400 µg of folic acid per day.
Participants will receive individualized hypocaloric low-carbohydrate diet counseling for 2 months.
Daily energy requirements will be calculated individually, and meal plans will be prescribed with an energy deficit of approximately 500 kcal/day to promote weight loss.
The diet will provide 50-130 g/day of carbohydrates or approximately 25-30% of total daily energy from carbohydrates.
After achieving the carbohydrate target, the remaining energy intake will be distributed to provide approximately 15-30% of total energy from protein and 35-50% from fat, according to individual energy requirements.
Dietary adherence will be monitored at regular follow-up visits throughout the intervention period.
|
|
Aktywny komparator: Low-Carbohydrate Diet Active Control Group
Participants in this arm will receive a hypocaloric low-carbohydrate diet together with folic acid supplementation.
Folic acid will be administered orally at a dose of 400 µg once daily.
No metformin or myo-inositol supplementation will be provided.
Folic acid is included to standardize folate intake across intervention groups, as the myo-inositol supplement used in the inositol groups also contains folic acid.
The intervention period will be 2 months.
|
Folic acid will be administered orally at a dose of 400 µg once daily for 2 months.
Folic acid is provided to participants in the metformin and control groups to standardize folate intake across intervention groups, as the myo-inositol supplement administered in the inositol groups also contains 400 µg of folic acid per day.
Participants will receive individualized hypocaloric low-carbohydrate diet counseling for 2 months.
Daily energy requirements will be calculated individually, and meal plans will be prescribed with an energy deficit of approximately 500 kcal/day to promote weight loss.
The diet will provide 50-130 g/day of carbohydrates or approximately 25-30% of total daily energy from carbohydrates.
After achieving the carbohydrate target, the remaining energy intake will be distributed to provide approximately 15-30% of total energy from protein and 35-50% from fat, according to individual energy requirements.
Dietary adherence will be monitored at regular follow-up visits throughout the intervention period.
|
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Change in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) from Baseline to 2 Months
Ramy czasowe: Baseline and 2 months
|
Insulin resistance will be assessed using the Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), calculated from fasting plasma glucose and fasting serum insulin concentrations.
The primary outcome will be the change in HOMA-IR from baseline to 2 months.
Lower HOMA-IR values indicate improved insulin sensitivity.
|
Baseline and 2 months
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Change in Body Weight From Baseline to 2 Months
Ramy czasowe: Baseline and 2 months
|
Body weight will be measured in kilograms (kg).
Change in body weight will be calculated as the value at 2 months minus the baseline value.
|
Baseline and 2 months
|
|
Change in Body Mass Index From Baseline to 2 Months
Ramy czasowe: Baseline and 2 months
|
Body mass index (BMI) will be calculated as body weight in kilograms divided by height in meters squared (kg/m²).
Change in BMI will be calculated as the value at 2 months minus the baseline value.
|
Baseline and 2 months
|
|
Change in Body Fat Percentage From Baseline to 2 Months
Ramy czasowe: Baseline to 2 Months
|
Body fat percentage will be assessed by bioelectrical impedance analysis (BIA) and reported as a percentage (%).
Change in body fat percentage will be calculated as the value at 2 months minus the baseline value.
|
Baseline to 2 Months
|
|
Change in Body Fat Mass From Baseline to 2 Months
Ramy czasowe: Baseline to 2 Months
|
Body fat mass will be assessed by bioelectrical impedance analysis (BIA) and reported in kilograms (kg).
Change in body fat mass will be calculated as the value at 2 months minus the baseline value.
|
Baseline to 2 Months
|
|
Change in Fasting Serum Visfatin Concentration (ng/mL) From Baseline to 2 Months
Ramy czasowe: Baseline to 2 Months
|
Fasting serum visfatin concentration will be measured in nanograms per milliliter (ng/mL) using an enzyme-linked immunosorbent assay (ELISA).
The outcome will be reported as the change in serum visfatin concentration from baseline to 2 months, calculated as the 2-month value minus the baseline value.
|
Baseline to 2 Months
|
Współpracownicy i badacze
Sponsor
Sponsor
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Szacowany)
Rozpoczęcie studiów
Zakończenie podstawowe (Szacowany)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Choroby układu moczowo-płciowego
- Choroby narządów płciowych
- Choroby układu hormonalnego
- Zaburzenia odżywiania
- Nowotwory
- Choroby układu moczowo-płciowego kobiet
- Choroby układu moczowo-płciowego kobiet i powikłania ciąży
- Choroby metaboliczne
- Przekarmienie
- Masy ciała
- Choroby narządów płciowych, kobiety
- Zaburzenia metabolizmu glukozy
- Choroby jajników
- Choroby przydatków
- Zaburzenia gonad
- Hiperinsulinizm
- Nadwaga
- Torbiele jajników
- Cysty
- Stany patologiczne, oznaki i objawy
- Choroby żywieniowe i metaboliczne
- Objawy i symptomy
- Otyłość
- Zespół policystycznych jajników
- Insulinooporność
- Organiczne chemikalia
- Związki heterocykliczne
- Związki heterocykliczne, 2-ring
- Związki heterocykliczne, sterowanie stopieniem
- Lecznictwo
- Dieta, żywność i odżywianie
- Zjawiska fizjologiczne
- Węglowodany
- Zjawiska fizjologiczne żywieniowe
- Alkohole
- Dieta, roślinna
- Terapia dietetyczna
- Terapia żywieniowa
- Dieta
- Pterins
- Perydyny
- Biguanides
- Guanidyny
- Śmiany
- Alkohole cukrowe
- Metformina
- Kwas foliowy
- Inozytol
- Dieta, Morza Śródziemna
- Dieta, ograniczona węglowodanami
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- DU-BVD-EU-01
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
produkt wyprodukowany i wyeksportowany z USA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .